Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression

Epidermal growth factor receptor (EGFR) is a causal factor in carcinoma, yet many carcinoma patients are resistant to EGFR inhibitors. Potential insight into this resistance stems from prior work that showed EGFR in normal epithelial cells docks to the extracellular domain of the plasma membrane pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Beauvais, DeannaLee M., Nelson, Scott E., Adams, Kristin M., Stueven, Noah A., Jung, Oisun, Rapraeger, Alan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190016/
https://www.ncbi.nlm.nih.gov/pubmed/35569509
http://dx.doi.org/10.1016/j.jbc.2022.102029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190016/
https://www.ncbi.nlm.nih.gov/pubmed/35569509
http://dx.doi.org/10.1016/j.jbc.2022.102029

Ejemplares similares